Kenvue Inc. $KVUE Shares Sold by Mirae Asset Global Investments Co. Ltd.

Key Points

• Mirae Asset Global Investments Co. Ltd. reduced its holdings in Kenvue Inc. by 12.4% during Q2, now owning 505,265 shares valued at approximately $10.57 million.
• Analysts have lowered their price targets for Kenvue, with Royal Bank of Canada setting a target of $22.00, while Barclays further decreased it to $17.00, reflecting a cautious outlook on the company's performance.
• Kenvue recently raised its quarterly dividend to $0.2075 per share, yielding approximately 5.3%, up from the previous dividend of $0.21.

Mirae Asset Global Investments Co. Ltd. lessened its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 12.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 505,265 shares of the company's stock after selling 71,584 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Kenvue were worth $10,575,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Pittenger & Anderson Inc. purchased a new position in shares of Kenvue during the first quarter worth $30,000. Trust Co. of Vermont lifted its holdings in shares of Kenvue by 266.8% in the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company's stock valued at $33,000 after buying an additional 1,150 shares during the period. TruNorth Capital Management LLC acquired a new position in shares of Kenvue in the 1st quarter valued at about $36,000. Truvestments Capital LLC purchased a new stake in shares of Kenvue in the first quarter worth about $37,000. Finally, Clal Insurance Enterprises Holdings Ltd grew its holdings in Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after acquiring an additional 1,287 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on KVUE. Royal Bank Of Canada lowered their price objective on Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a research report on Friday, August 8th. Barclays dropped their price target on shares of Kenvue from $20.00 to $17.00 and set an "equal weight" rating on the stock in a research report on Wednesday. Evercore ISI decreased their price objective on shares of Kenvue from $23.00 to $18.00 and set an "in-line" rating for the company in a research report on Tuesday, September 23rd. UBS Group lowered their target price on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a research note on Thursday, July 17th. Finally, The Goldman Sachs Group cut their price target on Kenvue from $22.00 to $19.00 and set a "neutral" rating for the company in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Kenvue presently has an average rating of "Hold" and a consensus target price of $22.46.

Kenvue Stock Up 0.4%

KVUE opened at $15.80 on Monday. The company has a market cap of $30.31 billion, a PE ratio of 21.34, a price-to-earnings-growth ratio of 2.27 and a beta of 0.72. Kenvue Inc. has a twelve month low of $15.47 and a twelve month high of $25.17. The company has a 50-day moving average price of $19.71 and a 200 day moving average price of $21.55. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same period in the previous year, the business earned $0.32 EPS. Kenvue's quarterly revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were issued a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 5.3%. The ex-dividend date was Wednesday, August 13th. This is an increase from Kenvue's previous quarterly dividend of $0.21. Kenvue's payout ratio is 112.16%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.